The iconic rise of Viagra has long been a benchmark of pharmaceutical success, yet its legacy within the broader industry now raises questions about future returns . Alternative versions are diminishing exclusivity , prompting anxieties that betting on companies significantly dependent to Viagra's former standing could be a speculative move , espec